MAPT and Alzheimer disease: Due to its high diagnostic accuracy [44], robust correlations with tau and amyloid pathology [45], and equivalency with validated CSF biomarkers in head-to-head investigations [46,47,48], p-tau217 has emerged as one of the most promising blood-based biomarkers for AD.